These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18273557)

  • 1. Docking and multivariate methods to explore HIV-1 drug-resistance: a comparative analysis.
    Almerico AM; Tutone M; Lauria A
    J Comput Aided Mol Des; 2008 May; 22(5):287-97. PubMed ID: 18273557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance.
    Masso M; Vaisman II
    BMC Genomics; 2013; 14 Suppl 4(Suppl 4):S3. PubMed ID: 24268064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase.
    García-Sosa AT; Sild S; Takkis K; Maran U
    J Chem Inf Model; 2011 Oct; 51(10):2595-611. PubMed ID: 21875140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
    Tabassum T; Azeem SM; Muwonge AN; Frey KM
    Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral Resistance Mutations (revised April 2001).
    ;
    HIV Clin Trials; 2001; 2(4):346-55. PubMed ID: 11590539
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Gago F
    J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins?
    Chen YZ; Gu XL; Cao ZW
    J Mol Graph Model; 2001; 19(6):560-70. PubMed ID: 11552685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
    Zhu M; Ma L; Wen J; Dong B; Wang Y; Wang Z; Zhou J; Zhang G; Wang J; Guo Y; Liang C; Cen S; Wang Y
    Eur J Med Chem; 2020 Jan; 186():111900. PubMed ID: 31771827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evolution of HIV resistance mutations in the Valme referral center].
    Nogales MC; Castro C; Martín-Mazuelos E
    Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):159. PubMed ID: 17288915
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain.
    Gallego O; Ruiz L; Vallejo A; Ferrer E; Rubio A; Clotet B; Leal M; Soriano V;
    AIDS; 2001 Sep; 15(14):1894-6. PubMed ID: 11579258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing antiretroviral drugs.
    Soriano V
    AIDS; 2001 Mar; 15(5):547-51. PubMed ID: 11316990
    [No Abstract]   [Full Text] [Related]  

  • 13. High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.
    Charpentier C; Bellecave P; Cisse M; Mamadou S; Diakite M; Peytavin G; Tchiombiano S; Teisseire P; Pizarro L; Storto A; Brun-Vézinet F; Katlama C; Calvez V; Marcelin AG; Masquelier B; Descamps D
    Antivir Ther; 2011; 16(3):429-33. PubMed ID: 21555827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Services for prediction of drug susceptibility for HIV proteases and reverse transcriptases at the HIV drug research centre.
    Spjuth O; Eklund M; Lapins M; Junaid M; Wikberg JE
    Bioinformatics; 2011 Jun; 27(12):1719-20. PubMed ID: 21493651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmission of zidovudine resistant strains of HIV-1: the first wave.
    Blower S
    AIDS; 2001 Nov; 15(17):2317-8. PubMed ID: 11698706
    [No Abstract]   [Full Text] [Related]  

  • 17. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 18. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
    Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
    J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.
    Shafer RW; Rhee SY; Pillay D; Miller V; Sandstrom P; Schapiro JM; Kuritzkes DR; Bennett D
    AIDS; 2007 Jan; 21(2):215-23. PubMed ID: 17197813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.